Open AccessSuccess rate of Remdesivir, Convalescent Plasma, and Tocilizumab in moderate to severe Covid-19 pneumonia: our experience in a tertiary care center
Author(s) -
Bijaya Mohanty,
Ashok Sunder,
Bhagyalakshmi Satyanarayan,
Manish Kumar,
Rishabh Shukla,
Asif Ahmed
Publication year - 2021
Publication title -
journal of family medicine and primary care
Language(s) - English
Resource type - Journals
eISSN - 2278-7135
pISSN - 2249-4863
DOI - 10.4103/jfmpc.jfmpc_578_21
Subject(s) - medicine , tocilizumab , pneumonia , radiological weapon , mortality rate , observational study , emergency medicine , surgery , disease
After the first case of Covid-19 was identified in Wuhan City, China, the numbers increased rapidly all over the world putting a huge burden on the entire healthcare system. Managing these cases posed a great challenge to the treating clinicians in the absence of targeted therapy. At this juncture, few modalities got approved as EUA (Emergency use under authorization) drugs namely Remdesivir, Convalescent Plasma (CP), and Tocilizumab (TCZ) to treat this deadly disease.